Iron, oxygen, and the pulmonary circulation

Journal of Applied Physiology

Volumn 119, Issue 12, 2015, Pages 1421-1431

  Frise, Matthew C ^a   Robbins, Peter A ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Highaltitude illness; Hypoxia; Hypoxia inducible factor; Hypoxic pulmonary vasoconstriction; Iron

Indexed keywords

IRON;

ALTITUDE DISEASE; ANIMAL; HUMAN; HYPOXIA; LUNG CIRCULATION; METABOLISM; OXYGEN CONSUMPTION; PATHOPHYSIOLOGY; VASOCONSTRICTION;

ALTITUDE SICKNESS; ANIMALS; HUMANS; HYPOXIA; IRON; OXYGEN CONSUMPTION; PULMONARY CIRCULATION; VASOCONSTRICTION;

EID: 84943362084     PISSN: 87507587     EISSN: 15221601     Source Type: Journal    
DOI: 10.1152/japplphysiol.00179.2015     Document Type: Review

References (107)

1. Agarwal R, Vasavada N, Sachs NG, Chase S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 65: 2279-2289, 2004.
2. Aldenderfer M. Peopling the Tibetan Plateau: insights from archaeology. High Alt Med Biol 12: 141-147, 2011.
3. Allemann Y, Sartori C, Lepori M, Pierre S, Melot C, Naeije R, Scherrer U, Maggiorini M. Echocardiographic and invasive measurements of pulmonary artery pressure correlate closely at high altitude. Am J Physiol Heart Circ Physiol 279: H2013-H2016, 2000.
4. Altamura S, Bartsch P, Dehnert C, Maggiorini M, Weiss G, Theurl I, Muckenthaler MU, Mairbaurl H. Increased hepcidin levels in high-altitude pulmonary edema. J Appl Physiol (1985) 118: 292-298, 2015.
5. Ang SO, Chen H, Hirota K, Gordeuk VR, Jelinek J, Guan Y, Liu E, Sergueeva AI, Miasnikova GY, Mole D, Maxwell PH, Stockton DW, Semenza GL, Prchal JT. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet 32: 614-621, 2002.
6. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Luscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P; FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361: 2436-2448, 2009.
7. Arai TJ, Henderson AC, Dubowitz DJ, Levin DL, Friedman PJ, Buxton RB, Prisk GK, Hopkins SR. Hypoxic pulmonary vasoconstriction does not contribute to pulmonary blood flow heterogeneity in normoxia in normal supine humans. J Appl Physiol (1985) 106: 1057-1064, 2009.
8. Asadi AK, Sa RC, Kim NH, Theilmann RJ, Hopkins SR, Buxton RB, Prisk GK. Inhaled nitric oxide alters the distribution of blood flow in the healthy human lung, suggesting active hypoxic pulmonary vasoconstriction in normoxia. J Appl Physiol (1985) 118: 331-343, 2015.
9. Aziz N, Munro HN. Iron regulates ferritin mRNA translation through a segment of its 5= untranslated region. Proc Natl Acad Sci USA 84: 8478-8482, 1987.
10. Balanos GM, Dorrington KL, Robbins PA. Desferrioxamine elevates pulmonary vascular resistance in humans: potential for involvement of HIF-1. J Appl Physiol 92: 2501-2507, 2002.
11. Balanos GM, Talbot NP, Robbins PA, Dorrington KL. Separating the direct effect of hypoxia from the indirect effect of changes in cardiac output on the maximum pressure difference across the tricuspid valve in healthy humans. Pflügers Arch 450: 372-380, 2005.
12. Bärtsch P, Mairbaurl H, Maggiorini M, Swenson ER. Physiological aspects of high-altitude pulmonary edema. J Appl Physiol (1985) 98: 1101-1110, 2005.
13. Beall CM, Cavalleri GL, Deng L, Elston RC, Gao Y, Knight J, Li C, Li JC, Liang Y, McCormack M, Montgomery HE, Pan H, Robbins PA, Shianna KV, Tam SC, Tsering N, Veeramah KR, Wang W, Wangdui P, Weale ME, Xu Y, Xu Z, Yang L, Zaman MJ, Zeng C, Zhang L, Zhang X, Zhaxi P, Zheng YT. Natural selection on EPAS1 (HIF2alpha) associated with low hemoglobin concentration in Tibetan highlanders. Proc Natl Acad Sci USA 107: 11459-11464, 2010.
14. Berk L, Burchenal JH, Castle WB. Erythropoietic effect of cobalt in patients with or without anemia. N Engl J Med 240: 754-761, 1949.
15. Bernhardt WM, Wiesener MS, Scigalla P, Chou J, Schmieder RE, Gunzler V, Eckardt KU. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol 21: 2151-2156, 2010.
16. Bishop T, Talbot NP, Turner PJ, Nicholls LG, Pascual A, Hodson EJ, Douglas G, Fielding JW, Smith TG, Demetriades M, Schofield CJ, Robbins PA, Pugh CW, Buckler KJ, Ratcliffe PJ. Carotid body hyperplasia and enhanced ventilatory responses to hypoxia in mice with heterozygous deficiency of PHD2. J Physiol 591: 3565-3577, 2013.
17. Bossone E, Rubenfire M, Bach DS, Ricciardi M, Armstrong WF. Range of tricuspid regurgitation velocity at rest and during exercise in normal adult men: implications for the diagnosis of pulmonary hypertension. J Am Coll Cardiol 33: 1662-1666, 1999.
18. Brusselmans K, Compernolle V, Tjwa M, Wiesener MS, Maxwell PH, Collen D, Carmeliet P. Heterozygous deficiency of hypoxiainducible factor-2alpha protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia. J Clin Invest 111: 1519-1527, 2003.
19. Cotroneo E, Ashek A, Wang L, Wharton J, Dubois O, Bozorgi S, Busbridge M, Alavian KN, Wilkins MR, Zhao L. Iron homeostasis and pulmonary hypertension: iron deficiency leads to pulmonary vascular remodeling in the rat. Circ Res 116: 1680-1690, 2015.
20. Croft QP, Formenti F, Talbot NP, Lunn D, Robbins PA, Dorrington KL. Variations in alveolar partial pressure for carbon dioxide and oxygen have additive not synergistic acute effects on human pulmonary vasoconstriction. PLoS One 8: e67886, 2013.
21. Currie PJ, Seward JB, Chan KL, Fyfe DA, Hagler DJ, Mair DD, Reeder GS, Nishimura RA, Tajik AJ. Continuous wave Doppler determination of right ventricular pressure: a simultaneous Dopplercatheterization study in 127 patients. J Am Coll Cardiol 6: 750-756, 1985.
22. Dorrington KL, Balanos GM, Talbot NP, Robbins PA. Extent to which pulmonary vascular responses to PCO2 and PO2 play a functional role within the healthy human lung. J Appl Physiol (1985) 108: 1084-1096, 2010.
23. Dorrington KL, Clar C, Young JD, Jonas M, Tansley JG, Robbins PA. Time course of the human pulmonary vascular response to 8 hours of isocapnic hypoxia. Am J Physiol Heart Circ Physiol 273: H1126-H1134, 1997.
24. Fatemian M, Herigstad M, Croft QP, Formenti F, Cardenas R, Wheeler C, Smith TG, Friedmannova M, Dorrington KL, Robbins PA. Determinants of ventilation and pulmonary artery pressure during early acclimatization to hypoxia in humans. J Physiol 2015 Apr 22. doi:10.1113/JP270061. [Epub ahead of print]
25. FitzGerald MP. The changes in the breathing and the blood at various high altitudes. Phil Trans Royal Soc B: Biol Sci 203: 351-371, 1913.
26. Formenti F, Beer PA, Croft QP, Dorrington KL, Gale DP, Lappin TR, Lucas GS, Maher ER, Maxwell PH, McMullin MF, O'Connor DF, Percy MJ, Pugh CW, Ratcliffe PJ, Smith TG, Talbot NP, Robbins PA. Cardiopulmonary function in two human disorders of the hypoxia-inducible factor (HIF) pathway: von Hippel-Lindau disease and HIF-2alpha gain-of-function mutation. FASEB J 25: 2001-2011, 2011.
27. Frise MC, Robbins PA. The pulmonary vasculature-lessons from Tibetans and from rare diseases of oxygen sensing. Exp Physiol 2014 Sep 1 [Epub ahead of print]
28. Ganz T, Nemeth E. Iron sequestration and anemia of inflammation. Semin Hematol 46: 387-393, 2009.
29. Gassmann M, Muckenthaler MU. Adaptation of iron requirement to hypoxic conditions in the ascending mountaineer. J Appl Physiol (1985) (First published July 16, 2015). doi:10.1152/japplphysiol.00248.2015. [Epub ahead of print]
30. Ghosh MC, Zhang DL, Jeong SY, Kovtunovych G, Ollivierre-Wilson H, Noguchi A, Tu T, Senecal T, Robinson G, Crooks DR, Tong WH, Ramaswamy K, Singh A, Graham BB, Tuder RM, Yu ZX, Eckhaus M, Lee J, Springer DA, Rouault TA. Deletion of iron regulatory protein 1 causes polycythemia and pulmonary hypertension in mice through translational derepression of HIF2alpha. Cell Metab 17: 271-281, 2013.
31. Goetze O, Schmitt J, Spliethoff K, Theurl I, Weiss G, Swinkels DW, Tjalsma H, Maggiorini M, Krayenbuhl P, Rau M, Fruehauf H, Wojtal KA, Mullhaupt B, Fried M, Gassmann M, Lutz T, Geier A. Adaptation of iron transport and metabolism to acute high-altitude hypoxia in mountaineers. Hepatology 58: 2153-2162, 2013.
32. Groves BM, Reeves JT, Sutton JR, Wagner PD, Cymerman A, Malconian MK, Rock PB, Young PM, Houston CS. Operation Everest II: elevated high-altitude pulmonary resistance unresponsive to oxygen. J Appl Physiol (1985) 63: 521-530, 1987.
33. Grünig E, Mereles D, Hildebrandt W, Swenson ER, Kübler W, Kuecherer H, Bärtsch P. Stress Doppler echocardiography for identification of susceptibility to high altitude pulmonary edema. J Am Coll Cardiol 35: 980-987, 2000.
34. Gunshin H, Allerson CR, Polycarpou-Schwarz M, Rofts A, Rogers JT, Kishi F, Hentze MW, Rouault TA, Andrews NC, Hediger MA. Iron-dependent regulation of the divalent metal ion transporter. FEBS Lett 509: 309-316, 2001.
35. Haldane JS Respiration. New Haven, CT: Yale Univ. Press, 1922.
36. Hentze MW, Caughman SW, Rouault TA, Barriocanal JG, Dancis A, Harford JB, Klausner RD. Identification of the iron-responsive element for the translational regulation of human ferritin mRNA. Science 238: 1570-1573, 1987.
37. Hopkins SR, Levin DL. Heterogeneous pulmonary blood flow in response to hypoxia: a risk factor for high altitude pulmonary edema? Respir Physiol Neurobiol 151: 217-228, 2006.
38. Howard LS, Barson RA, Howse BP, McGill TR, McIntyre ME, O'Connor DF, Robbins PA. Chamber for controlling end-tidal gas tensions over sustained periods in humans. J Appl Physiol (1985) 78: 1088-1091, 1995.
39. Howard LS, Watson GM, Wharton J, Rhodes CJ, Chan K, Khengar R, Robbins PA, Kiely DG, Condliffe R, Elliott CA, Pepke-Zaba J, Sheares K, Morrell NW, Davies R, Ashby D, Gibbs JS, Wilkins MR. Supplementation of iron in pulmonary hypertension: rationale and design of a phase II clinical trial in idiopathic pulmonary arterial hypertension. Pulm Circ 3: 100-107, 2013.
40. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS, Kaelin WG Jr. HIFalpha targeted for VHLmediated destruction by proline hydroxylation: implications for O2 sensing. Science 292: 464-468, 2001.
41. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, von Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292: 468-472, 2001.
42. Jafri S, Sivasothy P, Wells F, Morrell NW. Clinical demonstration of efficiency and reversibility of hypoxic pulmonary vasoconstriction in a patient presenting with unilateral incomplete bronchial occlusion. Pulm Circ 1: 119-121, 2011.
43. Jankowska EA, Kasztura M, Sokolski M, Bronisz M, Nawrocka S, Oleskowska-Florek W, Zymlinski R, Biegus J, Siwolowski P, Banasiak W, Anker SD, Filippatos G, Cleland JG, Ponikowski P. Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure. Eur Heart J 35: 2468-2476, 2014.
44. Kaelin WG Jr, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 30: 393-402, 2008.
45. Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet 46: 678-684, 2014.
46. Klip IT, Comin-Colet J, Voors AA, Ponikowski P, Enjuanes C, Banasiak W, Lok DJ, Rosentryt P, Torrens A, Polonski L, van Veldhuisen DJ, van der Meer P, Jankowska EA. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J 165: 575-582, 2013.
47. Knowles HJ, Mole DR, Ratcliffe PJ, Harris AL. Normoxic stabilization of hypoxia-inducible factor-1alpha by modulation of the labile iron pool in differentiating U937 macrophages: effect of natural resistanceassociated macrophage protein 1. Cancer Res 66: 2600-2607, 2006.
48. Lam CS, Borlaug BA, Kane GC, Enders FT, Rodeheffer RJ, Redfield MM. Age-associated increases in pulmonary artery systolic pressure in the general population. Circulation 119: 2663-2670, 2009.
49. Lee FS, Percy MJ. The HIF pathway and erythrocytosis. Annu Rev Pathol 6: 165-192, 2011.
50. Liu Q, Davidoff O, Niss K, Haase VH. Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis. J Clin Invest 122: 4635-4644, 2012.
51. Loenarz C, Schofield CJ. Expanding chemical biology of 2-oxoglutarate oxygenases. Nat Chem Biol 4: 152-156, 2008.
52. Lorenzo FR, Huff C, Myllymaki M, Olenchock B, Swierczek S, Tashi T, Gordeuk V, Wuren T, Ri-Li G, McClain DA, Khan TM, Koul PA, Guchhait P, Salama ME, Xing J, Semenza GL, Liberzon E, Wilson A, Simonson TS, Jorde LB, Kaelin WG Jr, Koivunen P, Prchal JT. A genetic mechanism for Tibetan high-altitude adaptation. Nat Genet 46: 951-956, 2014.
53. Lymboussaki A, Pignatti E, Montosi G, Garuti C, Haile DJ, Pietrangelo A. The role of the iron responsive element in the control of ferroportin1/IREG1/MTP1 gene expression. J Hepatol 39: 710-715, 2003.
54. Maxwell P, Salnikow K. HIF-1: an oxygen and metal responsive transcription factor. Cancer Biol Ther 3: 29-35, 2004.
55. Millet GP, Faiss R, Pialoux V. Point: Hypobaric hypoxia induces different physiological responses from normobaric hypoxia. J Appl Physiol (1985) 112: 1783-1784, 2012.
56. Mole DR. Iron homeostasis and its interaction with prolyl hydroxylases. Antioxid Redox Signal 12: 445-458, 2010.
57. Motley HL, Cournand A, Werko L, Himmelstein A, Dresdale D. The influence of short periods of induced acute anoxia upon pulmonary artery pressures in man. Am J Physiol 150: 315-320, 1947.
58. Moudgil R, Michelakis ED, Archer SL. Hypoxic pulmonary vasoconstriction. J Appl Physiol (1985) 98: 390-403, 2005.
59. Nagel S, Talbot NP, Mecinovic J, Smith TG, Buchan AM, Schofield CJ. Therapeutic manipulation of the HIF hydroxylases. Antioxid Redox Signal 12: 481-501, 2010.
60. Nickol AH, Frise MC, Cheng HY, McGahey A, McFadyen BM, Harris-Wright T, Bart NK, Curtis MK, Khandwala S, O'Neill DP, Pollard KA, Hardinge FM, Rahman NM, Armitage AE, Dorrington KL, Drakesmith H, Ratcliffe PJ, Robbins PA. A cross-sectional study of the prevalence and associations of iron deficiency in a cohort of patients with chronic obstructive pulmonary disease. BMJ Open 2015 Jul 6;5(7):e007911. doi:10.1136/bmjopen-2015-007911.
61. Pan Y, Mansfield KD, Bertozzi CC, Rudenko V, Chan DA, Giaccia AJ, Simon MC. Multiple factors affecting cellular redox status and energy metabolism modulate hypoxia-inducible factor prolyl hydroxylase activity in vivo and in vitro. Mol Cell Biol 27: 912-925, 2007.
62. Peacock AJ, Challenor V, Sutherland G. Estimation of pulmonary artery pressure by Doppler echocardiography in normal subjects made hypoxic. Respir Med 84: 335-337, 1990.
63. Petousi N, Croft QP, Cavalleri GL, Cheng HY, Formenti F, Ishida K, Lunn D, McCormack M, Shianna KV, Talbot NP, Ratcliffe PJ, Robbins PA. Tibetans living at sea level have a hyporesponsive hypoxiainducible factor system and blunted physiological responses to hypoxia. J Appl Physiol (1985) 116: 893-904, 2014.
64. Petousi N, Robbins PA. Human adaptation to the hypoxia of high altitude: the Tibetan paradigm from the pregenomic to the postgenomic era. J Appl Physiol (1985) 116: 875-884, 2014.
65. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, McDonagh T, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker SD; CONFIRM-HF Investigators. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 36: 657-668, 2015.
66. Qi X, Cui C, Peng Y, Zhang X, Yang Z, Zhong H, Zhang H, Xiang K, Cao X, Wang Y, Ouzhuluobu Basang Ciwangsangbu Bianba Gonggalanzi Wu T, Chen H, Shi H, Su B. Genetic evidence of paleolithic colonization and neolithic expansion of modern humans on the Tibetan plateau. Mol Biol Evol 30: 1761-1778, 2013.
67. Ren X, Dorrington KL, Maxwell PH, Robbins PA. Effects of desferrioxamine on serum erythropoietin and ventilatory sensitivity to hypoxia in humans. J Appl Physiol (1985) 89: 680-686, 2000.
68. Rhodes CJ, Howard LS, Busbridge M, Ashby D, Kondili E, Gibbs JS, Wharton J, Wilkins MR. Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension: clinical prevalence, outcomes, and mechanistic insights. J Am Coll Cardiol 58: 300-309, 2011.
69. Richalet JP, Souberbielle JC, Antezana AM, Dechaux M, Le Trong JL, Bienvenu A, Daniel F, Blanchot C, Zittoun J. Control of erythropoiesis in humans during prolonged exposure to the altitude of 6,542 m. Am J Physiol Regul Integr Comp Physiol 266: R756-R764, 1994.
70. Robbins PA, Swanson GD, Howson MG. A prediction-correction scheme for forcing alveolar gases along certain time courses. J Appl Physiol 52: 1353-1357, 1982.
71. Ruiter G, Lankhorst S, Boonstra A, Postmus PE, Zweegman S, Westerhof N, van der Laarse WJ, Vonk-Noordegraaf A. Iron deficiency is common in idiopathic pulmonary arterial hypertension. Eur Respir J 37: 1386-1391, 2011.
72. Sanchez M, Galy B, Muckenthaler MU, Hentze MW. Iron-regulatory proteins limit hypoxia-inducible factor-2alpha expression in iron deficiency. Nat Struct Mol Biol 14: 420-426, 2007.
73. Schneckenpointner R, Jorres RA, Meidenbauer N, Kollert F, Pfeifer M, Budweiser S. The clinical significance of anaemia and disturbed iron homeostasis in chronic respiratory failure. Int J Clin Pract 68: 130-138, 2014.
74. Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 5: 343-354, 2004.
75. Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell 148: 399-408, 2012.
76. Semenza GL. Oxygen sensing, homeostasis, and disease. N Engl J Med 365: 537-547, 2011.
77. Sheftel AD, Mason AB, Ponka P. The long history of iron in the Universe and in health and disease. Biochim Biophys Acta 1820: 161-187, 2012.
78. Shimoda LA, Laurie SS. HIF and pulmonary vascular responses to hypoxia. J Appl Physiol (1985) 116: 867-874, 2014.
79. Silverberg DS, Mor R, Weu MT, Schwartz D, Schwartz IF, Chernin G. Anemia and iron deficiency in COPD patients: prevalence and the effects of correction of the anemia with erythropoiesis stimulating agents and intravenous iron. BMC Pulm Med 14: 24, 2014.
80. Simonson TS, Yang Y, Huff CD, Yun H, Qin G, Witherspoon DJ, Bai Z, Lorenzo FR, Xing J, Jorde LB, Prchal JT, Ge R. Genetic evidence for high-altitude adaptation in Tibet. Science 329: 72-75, 2010.
81. Smith TG, Balanos GM, Croft QP, Talbot NP, Dorrington KL, Ratcliffe PJ, Robbins PA. The increase in pulmonary arterial pressure caused by hypoxia depends on iron status. J Physiol 586: 5999-6005, 2008.
82. Smith TG, Brooks JT, Balanos GM, Lappin TR, Layton DM, Leedham DL, Liu C, Maxwell PH, McMullin MF, McNamara CJ, Percy MJ, Pugh CW, Ratcliffe PJ, Talbot NP, Treacy M, Robbins PA. Mutation of von Hippel-Lindau tumour suppressor and human cardiopulmonary physiology. PLoS Med 3: e290, 2006.
83. Smith TG, Robbins PA, Ratcliffe PJ. The human side of hypoxiainducible factor. Br J Haematol 141: 325-334, 2008.
84. Smith TG, Talbot NP, Privat C, Rivera-Ch M, Nickol AH, Ratcliffe PJ, Dorrington KL, Leon-Velarde F, Robbins PA. Effects of iron supplementation and depletion on hypoxic pulmonary hypertension: two randomized controlled trials. JAMA 302: 1444-1450, 2009.
85. Soon E, Treacy CM, Toshner MR, MacKenzie-Ross R, Manglam V, Busbridge M, Sinclair-McGarvie M, Arnold J, Sheares KK, Morrell NW, Pepke-Zaba J. Unexplained iron deficiency in idiopathic and heritable pulmonary arterial hypertension. Thorax 66: 326-332, 2011.
86. Stevenson JG. Comparison of several noninvasive methods for estimation of pulmonary artery pressure. J Am Soc Echocardiogr 2: 157-171, 1989.
87. Sylvester JT, Shimoda LA, Aaronson PI, Ward JP. Hypoxic pulmonary vasoconstriction. Physiol Rev 92: 367-520, 2012.
88. Talbot NP, Balanos GM, Dorrington KL, Robbins PA. Two temporal components within the human pulmonary vascular response to approximately 2 h of isocapnic hypoxia. J Appl Physiol (1985) 98: 1125-1139, 2005.
89. Talbot NP, Croft QP, Curtis MK, Turner BE, Dorrington KL, Robbins PA, Smith TG. Contrasting effects of ascorbate and iron on the pulmonary vascular response to hypoxia in humans. Physiol Rep 2: e12220, 2014.
90. Talbot NP, Lakhal S, Smith TG, Privat C, Nickol AH, Rivera-Ch M, Leon-Velarde F, Dorrington KL, Mole DR, Robbins PA. Regulation of hepcidin expression at high altitude. Blood 119: 857-860, 2012.
91. Talbot NP, Smith TG, Privat C, Nickol AH, Rivera-Ch M, Leon-Velarde F, Dorrington KL, Robbins PA. Intravenous iron supplementation may protect against acute mountain sickness: a randomized, double-blinded, placebo-controlled trial. High Alt Med Biol 12: 265-269, 2011.
92. Tan Q, Kerestes H, Percy MJ, Pietrofesa R, Chen L, Khurana TS, Christofidou-Solomidou M, Lappin TR, Lee FS. Erythrocytosis and pulmonary hypertension in a mouse model of human HIF2A gain of function mutation. J Biol Chem 288: 17134-17144, 2013.
93. Toblli JE, Di Gennaro F, Rivas C. Changes in echocardiographic parameters in iron deficiency patients with heart failure and chronic kidney disease treated with intravenous iron. Heart Lung Circ 24: 686-695, 2015.
94. Upton PD, Morrell NW. The transforming growth factor-beta-bone morphogenetic protein type signalling pathway in pulmonary vascular homeostasis and disease. Exp Physiol 98: 1262-1266, 2013.
95. Viethen T, Gerhardt F, Dumitrescu D, Knoop-Busch S, Ten Freyhaus H, Rudolph TK, Baldus S, Rosenkranz S. Ferric carboxymaltose improves exercise capacity and quality of life in patients with pulmonary arterial hypertension and iron deficiency: a pilot study. Int J Cardiol 175: 233-239, 2014.
96. von Euler US, Liljestrand G. Observations on the pulmonary arterial blood pressure in the cat. Acta Physiol Scand 12: 301-320, 1946.
97. Wang GL, Semenza GL. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood 82: 3610-3615, 1993.
98. Wang GL, Semenza GL. Purification and characterization of hypoxiainducible factor 1. J Biol Chem 270: 1230-1237, 1995.
99. Weinstein DA, Roy CN, Fleming MD, Loda MF, Wolfsdorf JI, Andrews NC. Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood 100: 3776-3781, 2002.
100. Weitzenblum E, Loiseau A, Hirth C, Mirhom R, Rasaholinjanahary J. Course of pulmonary hemodynamics in patients with chronic obstructive pulmonary disease. Chest 75: 656-662, 1979.
101. Westcott RN, Fowler NO, Scott RC, Hauenstein VD, McGuire J. Anoxia and human pulmonary vascular resistance. J Clin Invest 30: 957-970, 1951.
102. Wilkinson N, Pantopoulos K. IRP1 regulates erythropoiesis and systemic iron homeostasis by controlling HIF2alpha mRNA translation. Blood 122: 1658-1668, 2013.
103. Yi X, Liang Y, Huerta-Sanchez E, Jin X, Cuo ZX, Pool JE, Xu X, Jiang H, Vinckenbosch N, Korneliussen TS, Zheng H, Liu T, He W, Li K, Luo R, Nie X, Wu H, Zhao M, Cao H, Zou J, Shan Y, Li S, Yang Q, Asan Ni P, Tian G, Xu J, Liu X, Jiang T, Wu R, Zhou G, Tang M, Qin J, Wang T, Feng S, Li G, Huasang Luosang J, Wang W, Chen F, Wang Y, Zheng X, Li Z, Bianba Z, Yang G, Wang X, Tang S, Gao G, Chen Y, Luo Z, Gusang L, Cao Z, Zhang Q, Ouyang W, Ren X, Liang H, Zheng H, Huang Y, Li J, Bolund L, Kristiansen K, Li Y, Zhang Y, Zhang X, Li R, Li S, Yang H, Nielsen R, Wang J, Wang J. Sequencing of 50 human exomes reveals adaptation to high altitude. Science 329: 75-78, 2010.
104. Yock PG, Popp RL. Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation 70: 657-662, 1984.
105. Yu AY, Shimoda LA, Iyer NV, Huso DL, Sun X, McWilliams R, Beaty T, Sham JS, Wiener CM, Sylvester JT, Semenza GL. Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1alpha. J Clin Invest 103: 691-696, 1999.
106. Zhang X, Zhang W, Ma SF, Miasniakova G, Sergueeva A, Ammosova T, Xu M, Nekhai S, Nourai M, Wade MS, Prchal JT, Garcia JG, Machado RF, Gordeuk VR. Iron deficiency modifies gene expression variation induced by augmented hypoxia sensing. Blood Cells Mol Dis 52: 35-45, 2014.
107. Zimmermann MB, Hurrell RF. Nutritional iron deficiency. Lancet 370: 511-520, 2007.